The atrial fibrillation and hypertension reactions were also associated with the Kir6.1-SUR2B blocking actions (Maqoud et al., 2021) and are a common and limiting reaction with long-term therapy with zoledronic acid. This evidence concerns the gene KCNJ8 and atrial fibrillation.